文献速递前列腺增生与排尿功能障碍

维贝格龙附加治疗对α1受体阻滞剂或PDE5抑制剂后持续储尿期症状男性的疗效与安全性初步研究

Efficacy and Safety of Vibegron Add-on Therapy in Men With Persistent Storage Symptoms After Receiving Alpha 1-Blocker or Phosphodiesterase 5 Inhibitor: A Preliminary Study.
PubMed 文献 · Urology · 2021-01-21

本研究对42例接受α1受体阻滞剂或PDE5抑制剂后仍有持续储尿期症状的良性前列腺增生男性患者,给予维贝格龙50mg附加治疗12周。结果显示OAB症状评分显著下降,储尿期症状相关问卷评分改善,最大尿流率和残余尿量无变化,无因不良事件停药。多因素回归分析显示OAB症状评分、CLSS评分、前列腺体积和α1受体阻滞剂单药治疗是影响维贝格龙疗效的独立因素。

要点

  • 维贝格龙50mg附加治疗12周可显著改善α1受体阻滞剂或PDE5抑制剂后持续储尿期症状。
  • 最大尿流率和残余尿量无变化,无患者因不良事件停药。
  • OAB症状评分、CLSS评分、前列腺体积和α1受体阻滞剂单药治疗是疗效独立影响因素。

核心结论

  • 对良性前列腺增生且持续储尿期症状患者,在α1受体阻滞剂或PDE5抑制剂单药治疗基础上附加维贝格龙有效且安全。

研究设计与样本

  • 前瞻性初步研究,纳入42例(72.0±8.2岁)持续储尿期症状男性,其中22例服用α1受体阻滞剂、20例服用PDE5抑制剂,维贝格龙50mg治疗12周。

主要发现

  • 多个问卷评分尤其是储尿期症状显著改善,但CLSS中压力性尿失禁、排尿用力、膀胱疼痛和尿道疼痛无显著改善。
  • 最大尿流率和残余尿量无变化,无患者因不良事件停用维贝格龙。
  • 多因素回归分析显示OAB症状评分、CLSS评分、前列腺体积和α1受体阻滞剂单药治疗是维贝格龙疗效的独立影响因素。

临床怎么用

  • 对于α1受体阻滞剂或PDE5抑制剂单药治疗后仍存在持续储尿期症状的BPH男性,可考虑附加维贝格龙50mg治疗12周。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate the efficacy and safety of vibegron add-on therapy in men with persistent storage symptoms receiving α-1 blockers or PDE5 inhibitor for benign prostatic hyperplasia and then determine the independent factors affecting the efficacy of vibegron. METHODS: Vibegron 50 mg was administered for 12 weeks to 42 patients (72.0 ± 8.2 years) with persistent storage symptoms who had taken α-1 blockers (22 patients) or PDE5 inhibitor (20 patients). The primary endpoint was change in the overactive Bladder (OAB) Symptom Score from baseline to end of treatment. The secondary endpoints were changes in each question of several questionnaires, maximum flow rate and residual urine volume. Finally, independent factors affecting the efficacy of vibegron were investigated. RESULTS: Total OAB Symptom Score was significantly decreased (6.21 ± 3.12 vs 4.38 ± 2.46; P < .001). Although each score of several questionnaires, especially for storage symptoms, improved significantly, no significant improvement was found in stress incontinence, straining, bladder pain and urethral pain in the Core Lower Urinary Tract Symptom score. Maximum flow rate and residual urine volume did not change, and no patient discontinued vibegron because of adverse events. Multiple regression analysis showed that OAB Symptom Score, Core Lower Urinary Tract Symptom score, prostate volume and monotherapy with α-1 blocker were independent factors affecting the efficacy of vibegron. CONCLUSION: Add-on therapy of vibegron to monotherapy with α-1 blockers or PDE5 inhibitor for patients with benign prostatic hyperplasia and persistent storage symptoms was effective and safe.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Ishikawa K, Tsujimura A, Miyoshi M, et al. Efficacy and Safety of Vibegron Add-on Therapy in Men With Persistent Storage Symptoms After Receiving Alpha 1-Blocker or Phosphodiesterase 5 Inhibitor: A Preliminary Study. Urology. 2021. PMID: 33484823. doi:10.1016/j.urology.2021.01.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。